I hope I have given some insight into how cost models are being used to evaluate the use of disposables technologies in biopharmaceutical
manufacturing. I believe that the current focus on COGS models is underplaying the benefits of disposables technology. Typically,
disposable technologies result in quicker builds of new facilities or manufacturing suites and reduced capital expenditures.
The financial analysis should capture these benefits by accounting for this delay in spending (thereby reducing the project
risk). The best method for accounting for these benefits is through the use of NPV analysis.
Andrew Sinclair is the managing director of Biopharm Services, Chesham, Bucks, UK, +44 1494 793 243, email@example.com
1. Sinclair A, Monge M. Biomanufacturing for the 21st century: Designing a concept facility based on single-use systems.
Bioprocess Int. 2004 Oct supp;26–31.
2. Lim J, Sinclair A, Kim D, Gottschalk U. Economic benefits of single-use membrane chromatography in polishing: a cost of
goods model. Bioprocess Int. 2007 Feb; 5(2):48–56.
3. Van Reiss R. Genentech. IBC IBC Bioeconomics Conference; 1999; Washington, DC.
4. Lim J, Sinclair A. Process economy of disposable manufacturing. Process models to minimize upfront investment. Amer Pharm
Rev. 2007 Sept/Oct;10(6):114–21.
5. Sinclair A, Monge M. Concept facility based on single-use systems, part 2. Leading the way for biomanufacturing in the
21st century. BioProcess Int. 2005 Oct supp;51–55.